[go: up one dir, main page]

MX2012010161A - Metodo para tratar el mal de parkinson. - Google Patents

Metodo para tratar el mal de parkinson.

Info

Publication number
MX2012010161A
MX2012010161A MX2012010161A MX2012010161A MX2012010161A MX 2012010161 A MX2012010161 A MX 2012010161A MX 2012010161 A MX2012010161 A MX 2012010161A MX 2012010161 A MX2012010161 A MX 2012010161A MX 2012010161 A MX2012010161 A MX 2012010161A
Authority
MX
Mexico
Prior art keywords
dosage form
amount ranging
carbidopa
inhibitor
weight
Prior art date
Application number
MX2012010161A
Other languages
English (en)
Other versions
MX336187B (es
Inventor
Pekka Maennistoe
Juha Rouru
Mikko Kuoppamaeki
Juha Ellmen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2012010161A publication Critical patent/MX2012010161A/es
Publication of MX336187B publication Critical patent/MX336187B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona un método pata el tratamiento del mal de Parkinson que comprende administrar de manera simultánea o secuencial a un paciente que necesite del tratamiento del mal de Parkinson una forma de dosificación que comprende (i) levodopa en una cantidad que va desde 50 mg a 300 mg, (ii) carbidopa en una cantidad que va desde 25 mg a 150 mg o una cantidad terapéuticamente equivalente de otro inhibidor de descarboxilasa aminoácido aromático, y (iii) entacapona en una cantidad que va desde 50 mg a 300 mg, en donde la proporción de entacapona a carbidopa en dicha forma de dosificación está en un intervalo de 0.3:1.0 a 3.2:1.0 por peso, un inhibidor COMT moderadamente potente en una cantidad que va desde 25 mg a 200 mg, en donde la proporción de dicho inhibidor COMT a carbidopa en dicha forma de dosificación está en un intervalo de 0.16:1.0 a 3.08:1.0 por peso, o un inhibidor CQMT altamente potente en una, cantidad que va desde 1 mg a 100 mg, en donde la proporción de dicho inhibidor COMT a carbidopa en dicha forma de dosificación está en un intervalo, de 0.006:1.0 a 1.54:1.0 por peso. También se describe la forma de dosificación farmacéutica utilizada en dicho método.
MX2012010161A 2010-03-04 2011-03-03 Metodo para tratar el mal de parkinson. MX336187B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US41282110P 2010-11-12 2010-11-12
US201161438416P 2011-02-01 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Publications (2)

Publication Number Publication Date
MX2012010161A true MX2012010161A (es) 2012-10-03
MX336187B MX336187B (es) 2016-01-07

Family

ID=44065577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010161A MX336187B (es) 2010-03-04 2011-03-03 Metodo para tratar el mal de parkinson.

Country Status (14)

Country Link
US (4) US20130137729A1 (es)
EP (1) EP2542220B1 (es)
JP (2) JP5774610B2 (es)
KR (1) KR101868326B1 (es)
CN (1) CN102781424B (es)
AU (1) AU2011222856B2 (es)
BR (1) BR112012018256A8 (es)
CA (1) CA2784819C (es)
EA (1) EA026419B1 (es)
ES (1) ES2614179T3 (es)
IL (1) IL221744A (es)
MX (1) MX336187B (es)
WO (1) WO2011107653A2 (es)
ZA (1) ZA201205836B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PL2481410T3 (pl) 2007-01-31 2017-03-31 Bial - Portela & Ca., S.A. Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania
JP2011514380A (ja) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー，エス．エー． ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
AU2011222856B2 (en) * 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
ES2955693T3 (es) * 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
SI3341380T1 (sl) * 2015-08-27 2020-02-28 Prexton Therapeutics Sa Možgansko-penetranten derivat kromon oksima za terapijo levodopa-inducirane diskinezije
ES3053690T3 (en) * 2018-03-23 2026-01-23 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US12251365B2 (en) 2018-11-15 2025-03-18 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2005063696A2 (de) 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
ES2390126T3 (es) 2004-06-04 2012-11-06 Xenoport, Inc. Derivados de levodopa, y composicones y usos de la misma
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
ES2311442T3 (es) * 2005-06-08 2010-01-07 Orion Corporation Un metood para la fabricacion de granulos que contienen entacapona para formas de dosificacion oral.
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
TWI403493B (zh) 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
WO2008053297A2 (en) 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
KR20100126452A (ko) 2008-02-28 2010-12-01 바이알 - 포르텔라 앤드 씨에이 에스에이 난용성 약물용 약학적 조성물
CN102170869A (zh) * 2008-08-22 2011-08-31 沃克哈特研究中心 包含左旋多巴、卡比多巴和恩他卡朋或其盐的单次单位口服剂量药物组合物
ES2476765T3 (es) * 2008-08-22 2014-07-15 Wockhardt Limited Composición farmacéutica de liberación sostenida de entacapona o sales de la misma
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
AU2011222856B2 (en) * 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Ｐｆｕ 摩擦係数推定装置および摩擦係数推定方法
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Also Published As

Publication number Publication date
MX336187B (es) 2016-01-07
US12521363B2 (en) 2026-01-13
KR20130006638A (ko) 2013-01-17
ZA201205836B (en) 2014-01-29
EA026419B1 (ru) 2017-04-28
WO2011107653A8 (en) 2012-08-02
US10857120B2 (en) 2020-12-08
CN102781424A (zh) 2012-11-14
BR112012018256A8 (pt) 2017-12-19
EA201290865A1 (ru) 2013-02-28
CN102781424B (zh) 2016-03-30
BR112012018256A2 (es) 2011-09-09
AU2011222856B2 (en) 2015-10-15
CA2784819A1 (en) 2011-09-09
CA2784819C (en) 2018-02-13
US20130137729A1 (en) 2013-05-30
US20240050394A1 (en) 2024-02-15
EP2542220B1 (en) 2016-11-02
KR101868326B1 (ko) 2018-06-19
IL221744A (en) 2016-11-30
HK1177896A1 (zh) 2013-08-30
US11771675B2 (en) 2023-10-03
US20210085635A1 (en) 2021-03-25
ES2614179T3 (es) 2017-05-30
JP2013521263A (ja) 2013-06-10
JP2015180644A (ja) 2015-10-15
JP5774610B2 (ja) 2015-09-09
US20150150839A1 (en) 2015-06-04
WO2011107653A2 (en) 2011-09-09
AU2011222856A1 (en) 2012-07-26
WO2011107653A3 (en) 2011-11-03
EP2542220A2 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
MX2012010161A (es) Metodo para tratar el mal de parkinson.
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
BR112014008036A2 (pt) tratamento de rinite
DOP2017000105A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
MX350046B (es) Tratamientos para trastornos gastrointestinales.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2019009244A (es) FORMULACION PARA ANTICUERPO ANTI -A4ß7.
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
BR112015010396A2 (pt) terapia de combinação
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
AR124078A1 (es) Método para el tratamiento de la enfermedad de parkinson
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112015012497A2 (pt) combinações farmacêuticas
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
UY31826A (es) Compuesto peptídico y su uso
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
NZ591328A (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof